β2M aberrations including multiple early frameshift mutations, absence of tumor-specific β2M protein expression, and loss of heterozygosity overlapping β2M were reported to occur in about 30% of melanoma patients with progressive disease after anti-PD-1 therapy, leading to a total loss of MHC-I [44]. This evidence concerns the gene B2M and neoplasm.